Australian pharmaceutical firm Hatchtech has appointment Timothy Waugh as chief executive.
Waugh has worked in the pharmaceutical industry for 27 years and has spent the last 10 years with Roche in the US as a divisional vice president.
Paul Kelly, Hatchtech’s chairman, said: ‘Tim’s skill set and extensive experience will be a strong addition and complement those existing in the company. The Board is confident this management team will serve us well as we take the company into the next stage of developing and commercialising DeOvo for the global marketplace.’
DeOvo is a topical formulation of a known metalloprotease inhibitor and offer the potential for a head lice control treatment that requires only one application.
Waugh said he looks forward to working with Hatchtech’s Board and management team as it review the results of the Phase IIb study and plan for the next stages of its clinical development.
Waugh will join the Board of Hatchtech and will be based in New Jersey, US.
Hatchtech appoints Tim Waugh as ceo
Formerly with Roche in the US as a divisional vice president
You may also like
Research & Development
![Adragos signs agreement with Towa Pharmaceutical to supply off-patent medicines]()
Adragos signs agreement with Towa Pharmaceutical to supply off-patent medicines
Adragos Pharma Kawagoe KK has announced the signing of an agreement with Towa Pharmaceutical Co., Ltd, to establish a strategic collaboration aimed at ensuring the stable supply of off-patent pharmaceuticals
Cell & Gene Therapy
![Vitalant adds NGS testing to Pittsburgh lab as part of national cell and gene therapy strategy]()
Vitalant adds NGS testing to Pittsburgh lab as part of national cell and gene therapy strategy
The expansion connects Phoenix, San Francisco and Pittsburgh laboratories into a hub-and-spoke model, strengthening analytical support for CGT development, transfusion medicine and inherited bleeding disorder diagnostics
Marketing
![CPHI Milan introduces new specialist AI, cold chain, contamination control and labelling zones at this year's event]()
CPHI Milan introduces new specialist AI, cold chain, contamination control and labelling zones at this year's event
CPHI Milan 2026, one of the pharmaceutical industry's largest global events, has launched four specialist zones designed to connect pharmaceutical companies with the technologies, services and expertise shaping the future of healthcare manufacturing and supply chains
Analysis
![AP Connect 4.0 strengthens data management and traceability in connected laboratories]()
AP Connect 4.0 strengthens data management and traceability in connected laboratories
Anton Paar has announced the latest update of its lab execution system, AP Connect 4.0, featuring enhanced capabilities for centralised user management, secure data handling, and improved traceability across laboratory workflows
